S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

KTTA Pasithea Therapeutics Corporation

2.0972

-0.0428 (-2.00%)

Last Updated: 02:04:48

Delayed by 15 minutes

Big Mid-Week Move From This Small Biotech

A Florida-based biotech company found quite a bit of mid-week success after it said that an external safety review committee recommended that its Phase 1 clinical trial of PAS-004...

To read the full story on AllPennyStocks.com, click here.

Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Pasithea Therapeutics Charts.

Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Pasithea Therapeutics Charts.

Pasithea Therapeutics Corporation News

Big Mid-Week Move From This Small Biotech
Thursday 6 February 2025 (2 days ago) • AllPennyStocks.com

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Wednesday 5 February 2025 (2 days ago) • GlobeNewswire Inc.

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4
Wednesday 15 January 2025 (3 weeks ago) • GlobeNewswire Inc.

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Wednesday 20 November 2024 (3 months ago) • GlobeNewswire Inc.

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Friday 27 September 2024 (4 months ago) • GlobeNewswire Inc.

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Thursday 26 September 2024 (4 months ago) • GlobeNewswire Inc.

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
Monday 9 September 2024 (5 months ago) • GlobeNewswire Inc.

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board
Tuesday 3 September 2024 (5 months ago) • GlobeNewswire Inc.

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Wednesday 28 August 2024 (5 months ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 14 August 2024 (6 months ago) • Edgar (US Regulatory)

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial
Thursday 13 June 2024 (8 months ago) • GlobeNewswire Inc.

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
Tuesday 28 May 2024 (8 months ago) • GlobeNewswire Inc.

More Pasithea Therapeutics Corporation News Articles

L&G Japan Equity UCITS E...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions